US EditionCAR T-Cell Therapy Boosts PFS in Advanced Gastric Cancer
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
CAR T-Cell Therapy Boosts PFS in Advanced Gastric Cancer
TOPLINE In patients with advanced Claudin-18 isoform 2 (CLDN18.2) -positive gastric or gastroesophageal junction cancers, satricabtagene autoleucel (satri-cel) chimeric antigen receptor (CAR) T-cell therapy significantly extended progression-free survival (PFS) compared with treatment of physician’s choice (TPC). METHODOLOGY CLDN18.2, a tight-junction protein, is overexpressed in patients with gastric and gastroesophageal junction (GEJ) cancers.…
The advanced therapies have not only been erected in the new Lighthouse of Alexandria that guides specialties such as Hematology and Hemotherapy or Immunology, but has also gained prominence within the Hospitalary Pharmacy. These cell and gene treatments represent a real care challenge, so the role of the pharmacist is transcendental to carry out optimal care and research. Not only that. This health figure must be "star" in the supervision of cl…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
